Proton pump inhibitor
![](http://s9.addthis.com/button1-share.gif)
In medicine, specifically gastroenterology, proton pump inhibitors (PPI) are medications that "inhibit H(+)-K(+)-exchanging atpase. They are used as anti-ulcer agents and sometimes in place of histamine H2 antagonists for gastroesophageal reflux disease."[1] They are also used to eradicate Helicobacter pylori, in combination with antibiotics.
Examples:
- Esomeprazole. Available as generic.
- Lansoprazole. Available as generic.
- Omeprazole. Available as non-prescription in the United States.
- Pantoprazole. Available as generic.
- Rabeprazole
Metabolism
Proton pump inhibitors are metabolized by the CYP2C19 isoenzyme of cytochrome P-450. Lanzoprazole is the strongest inhibitor of CYP2C19,[2] This may be less true for pantoprazole and esomeprazole.[3] Pantoprazole is the strongest inhibitor of the CYP2C9 isoenzyme[2]
Effectiveness
Proton pump inhibitors may improve:
- Non-ulcer dyspepsia[4]
- Gastroesophageal reflux disease[5] Medications may be taken as needed.[6] Two weeks of therapy may be adequate.[7]
- Reflux esophagitis[8]
PPIs may reduce the risk of gastrointestinal hemorrhage among patients undering anticoagulation.[9]
Adverse effects
Proton pump inhibitors may be associated with spontaneous bacterial peritonitis.[10] Recent starting of these drugs may also be associated with pneumonia acquired in the community[11]or hospital[12]. These drugs may be associated with Clostridium difficile diarrhea[13], and fractures other than hip fractures[14].
Starting proton pump inhibitors in healthy volunteers may induce acid-related symptoms when PPIs are stopped[15] This is problematic considering how often PPIs are incorrectly prescribed.[16]
Proton pump inhibitors may induce acid-related symptoms in healthy volunteers after withdrawal, presumably due to rebound acid hypersecretion.[15]
Drug interactions
In the United States, the Food and Drug Administration has issued warnings regarding combining PPIs with clopidogrel.[17][18] Proton pump inhibitors (especially inhibitors other than pantoprazole[19]), which are metabolized by the CYP2C19 isoenzyme of cytochrome P-450, may[20] or may not[21] increase adverse cardiac events when given to patients taking clopidogrel for coronary heart disease.
Trial | Patients | Intervention | Comparison | Outcome | Results | |
---|---|---|---|---|---|---|
PPI | Control | |||||
COGENT Randomized controlled trial[22] 2010 |
3,873 patients with an indication for dual antiplatelet • 94% were anglo |
1,033 concurrent users of clopidogrel and PPIs • all used omeprazole |
Placebo | Serious cardiovascular disease | ||
Odds ratio = 0.99; 95% CI, 0.68 - 1.44; P=0.96); "There was no apparent cardiovascular interaction between clopidogrel" | ||||||
Stockl et al Retrospective cohort study[23] 2010 |
2,066 patients hospitalized for myocardial infarction or stent | 1,033 concurrent users of clopidogrel and PPIs • 64% used pantoprazole |
1,033 patients not taking PPIs | Serious cardiovascular disease | ||
Odds ratio = 1.64 (95% CI 1.16-2.32) "Patients who received clopidogrel plus a PPI had a significantly higher risk of rehospitalization for MI or coronary stent placement than did patients receiving clopidogrel alone" | ||||||
Tennessee Medicaid cohort study[24] | 20,596 patients hospitalized for myocardial infarction, myocardial revascularization, or unstable angina pectoris | 7593 concurrent users of clopidogrel and PPIs • 62% used pantoprazole |
13003 patients not taking PPIs | Serious cardiovascular disease | ||
"Serious cardiovascular disease was not increased; however, the 95% CI included a clinically important increased risk" | ||||||
Ontario nested case-control study[19] | 13,636 subjects taking clopidogrel after myocardial infarction | 782 subjects readmitted for myocardial infarction | 2057 subjects not readmitted | Rate of PPI usage other than pantoprazole | Odds ratio = 1.40 (95% CI 1.10–1.77) | |
Cohort study from the VA Cardiac Care Follow-up Clinical Study[20] | 8205 subjects with acute coronary syndrome | 64% were taking PPIs: • 0.2% used pantoprazole • 50% received stents • Probably < 50% used drug eluting stents[27] |
Subjects not taking PPIs | Major vascular events | 29.8% | 20.8% |
Odds ratio = 1.25 (95% CI: 1.11-1.41) • "each 10% increase in the proportion of time taking clopidogrel plus PPI during follow-up was associated with a higher risk" | ||||||
Cohort study taken from TRITON-TIMI 38 randomized controlled trials[21][28][29] 2 of 14 authors disclosed payments from AstraZenca, the maker of omeprazole and esomeprazole |
6795 subjects with acute coronary syndrome who were randomized to the clopidogrel arm of the trial | 33% (4529) were taking PPIs at randomization: • 2814 took PPIs for duration of study • 41% used pantoprazole • 94% received stents • 47% received at least one drug eluting stent |
Subjects not taking PPIs | Major vascular events | 11.8% | 12.2% |
• Patients taking any PPI HR = 0.94, (95% CI 0.80–1.11) • Patients taking any PPI for duration of study HR = 1.05 (95% CI 0.85–1.30) • Results similar for each individual PPI • Results also insignificant when restricted to analysis of patients with a reduced function allele | ||||||
Medco cohort study[25] | 16,718 subjects who took clopidogrel for 12 months after coronary stent | 41% were taking PPIs: • 24% used pantoprazole • 100% received stents • Unknown use of drug eluting stents |
Subjects not taking PPIs | Major vascular events | 24% to 29% | 17.9% |
• Pantoprazole HR=1.61 (pantoprazole had most GI bleeding) • Esoprazole HR=1.57 • Lansoprazole HR=1.39 • Omeprazole HR=1.39 • Histamine H2 antagonists HR=1.14 (insignicant) | ||||||
Danish cohort study[26] | 56,406 subjects discharged after first-time myocardial infarction | • 44% received clopidogrel • 41% were taking PPIs: • 30% of PPIs were pantoprazole |
Subjects not taking PPIs | Cardiovascular deaths and rehospitalization for myocardial infarction or strokes | 26.3% | 18.6% |
• Any PPI HR=1.29 • Clopidogrel was associated with more adverse outcomes among patients taking PPIs and patient not taking PPIs. The increase due to clopidogrel was the same in both groups. |
References
- ↑ Anonymous (2024), Proton pump inhibitor (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ 2.0 2.1 Li XQ, Andersson TB, Ahlström M, Weidolf L (2004). "Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.". Drug Metab Dispos 32 (8): 821-7. PMID 15258107.
- ↑ Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B (January 2009). "Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel". Am. Heart J. 157 (1): 148.e1–5. DOI:10.1016/j.ahj.2008.09.017. PMID 19081411. Research Blogging.
- ↑ Moayyedi P, Soo S, Deeks J, Delaney B, Innes M, Forman D (2006). "Pharmacological interventions for non-ulcer dyspepsia.". Cochrane Database Syst Rev (4): CD001960. DOI:10.1002/14651858.CD001960.pub3. PMID 17054151. Research Blogging. Review in: Evid Based Med. 2007 Jun;12(3):79
- ↑ van Pinxteren B, Numans ME, Bonis PA, Lau J (2006). "Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.". Cochrane Database Syst Rev 3: CD002095. DOI:10.1002/14651858.CD002095.pub3. PMID 16855986. Research Blogging.
- ↑ Pace F, Tonini M, Pallotta S, Molteni P, Porro GB (2007). "Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken 'on-demand'.". Aliment Pharmacol Ther 26 (2): 195-204. DOI:10.1111/j.1365-2036.2007.03381.x. PMID 17593065. Research Blogging. Review in: Evid Based Med. 2007 Dec;12(6):177 Review in: ACP J Club. 2007 Nov-Dec;147(3):69
- ↑ Bardhan KD, Müller-Lissner S, Bigard MA, Bianchi Porro G, Ponce J, Hosie J et al. (1999). "Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study Group.". BMJ 318 (7182): 502-7. PMID 10024259. PMC PMC27748.
- ↑ Khan M, Santana J, Donnellan C, Preston C, Moayyedi P (2007). "Medical treatments in the short term management of reflux oesophagitis.". Cochrane Database Syst Rev (2): CD003244. DOI:10.1002/14651858.CD003244.pub2. PMID 17443524. Research Blogging.
- ↑ Massó González EL, García Rodríguez LA (2008). "Proton pump inhibitors reduce the long-term risk of recurrent upper gastrointestinal bleeding: an observational study.". Aliment Pharmacol Ther 28 (5): 629-37. DOI:10.1111/j.1365-2036.2008.03780.x. PMID 18616644. Research Blogging.
- ↑ Bajaj JS, Zadvornova Y, Heuman DM, et al. (May 2009). "Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites". Am. J. Gastroenterol. 104 (5): 1130–4. DOI:10.1038/ajg.2009.80. PMID 19337238. Research Blogging.
- ↑ Sarkar M, Hennessy S, Yang YX (2008). "Proton-pump inhibitor use and the risk for community-acquired pneumonia.". Ann Intern Med 149 (6): 391-8. PMID 18794558.
- ↑ Herzig SJ, Howell MD, Ngo LH, Marcantonio ER (2009). "Acid-suppressive medication use and the risk for hospital-acquired pneumonia.". JAMA 301 (20): 2120-8. DOI:10.1001/jama.2009.722. PMID 19470989. Research Blogging.
- ↑ Linsky A, Gupta K, Lawler EV, Fonda JR, Hermos JA (2010). "Proton pump inhibitors and risk for recurrent Clostridium difficile infection.". Arch Intern Med 170 (9): 772-8. DOI:10.1001/archinternmed.2010.73. PMID 20458084. Research Blogging.
- ↑ Gray SL, LaCroix AZ, Larson J, Robbins J, Cauley JA, Manson JE et al. (2010). "Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative.". Arch Intern Med 170 (9): 765-71. DOI:10.1001/archinternmed.2010.94. PMID 20458083. Research Blogging.
- ↑ 15.0 15.1 Reimer C, Søndergaard B, Hilsted L, Bytzer P (2009). "Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy.". Gastroenterology 137 (1): 80-7, 87.e1. DOI:10.1053/j.gastro.2009.03.058. PMID 19362552. Research Blogging.
Cite error: Invalid
<ref>
tag; name "pmid19362552" defined multiple times with different content - ↑ Wohlt PD, Hansen LA, Fish JT (2007). "Inappropriate continuation of stress ulcer prophylactic therapy after discharge.". Ann Pharmacother 41 (10): 1611-6. DOI:10.1345/aph.1K227. PMID 17848420. Research Blogging.
- ↑ Anonymous. (2009) Early Communication about an Ongoing Safety Review of clopidogrel bisulfate (marketed as Plavix)
- ↑ Anonymous (11/17/2009) Information for Healthcare Professionals: Update to the labeling of Clopidogrel Bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC)
- ↑ 19.0 19.1 19.2 Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV et al. (2009). "A population-based study of the drug interaction between proton pump inhibitors and clopidogrel.". CMAJ 180 (7): 713-8. DOI:10.1503/cmaj.082001. PMID 19176635. PMC PMC2659819. Research Blogging. Review in: Ann Intern Med. 2009 Aug 18;151(4):JC2-13 Review in: Evid Based Med. 2009 Oct;14(5):154
- ↑ 20.0 20.1 20.2 Ho PM, Maddox TM, Wang L, et al. (March 2009). "Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome". JAMA 301 (9): 937–44. DOI:10.1001/jama.2009.261. PMID 19258584. Research Blogging.
- ↑ 21.0 21.1 21.2 O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y et al. (2009). "Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.". Lancet 374 (9694): 989-97. DOI:10.1016/S0140-6736(09)61525-7. PMID 19726078. Research Blogging.
- ↑ 22.0 22.1 Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ et al. (2010). "Clopidogrel with or without omeprazole in coronary artery disease.". N Engl J Med 363 (20): 1909-17. DOI:10.1056/NEJMoa1007964. PMID 20925534. Research Blogging.
- ↑ 23.0 23.1 Stockl, Karen M.; Lisa Le, Armen Zakharyan, Ann S. M. Harada, Brian K. Solow, Joseph E. Addiego, Scott Ramsey (2010-04-26). "Risk of Rehospitalization for Patients Using Clopidogrel With a Proton Pump Inhibitor". Arch Intern Med 170 (8): 704-710. DOI:10.1001/archinternmed.2010.34. Retrieved on 2010-04-27. Research Blogging.
- ↑ 24.0 24.1 Ray WA, Murray KT, Griffin MR, Chung CP, Smalley WE, Hall K et al. (2010). "Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study.". Ann Intern Med 152 (6): 337-45. DOI:10.1059/0003-4819-152-6-201003160-00003. PMID 20231564. Research Blogging.
- ↑ 25.0 25.1 Stanek EJ et al. (2009) A National Study of the Effect of Individual Proton Pump Inhibitors on Cardiovascular Outcomes in Patients Treated with Clopidogrel Following Coronary Stenting: The Clopidogrel Medco Outcomes Study Society for Cardiovascular Angiography and Interventions 2009 Annual Meeting
- ↑ 26.0 26.1 Charlot M, Ahlehoff O, Norgaard ML, Jørgensen CH, Sørensen R, Abildstrøm SZ et al. (2010). "Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study.". Ann Intern Med 153 (6): 378-86. DOI:10.1059/0003-4819-153-6-201009210-00005. PMID 20855802. Research Blogging.
- ↑ Ho PM, Fihn SD, Wang L, Bryson CL, Lowy E, Maynard C et al. (2007). "Clopidogrel and long-term outcomes after stent implantation for acute coronary syndrome.". Am Heart J 154 (5): 846-51. DOI:10.1016/j.ahj.2007.08.028. PMID 17967588. Research Blogging.
- ↑ Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT et al. (2009). "Cytochrome p-450 polymorphisms and response to clopidogrel.". N Engl J Med 360 (4): 354-62. DOI:10.1056/NEJMoa0809171. PMID 19106084. Research Blogging.
- ↑ Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S et al. (2007). "Prasugrel versus clopidogrel in patients with acute coronary syndromes.". N Engl J Med 357 (20): 2001-15. DOI:10.1056/NEJMoa0706482. PMID 17982182. Research Blogging.